Broad Antiviral Therapy with Membrane-Modifying Small Molecules

Effective against a broad-spectrum of viruses. HIV Hepatitis C (HCV) Herpes Simplex Virus (HSV) Highly infectious viruses (ex: Ebola, Rift Valley fever viruses, etc.) Likely to be well-tolerated, since it is an endogenously produced molecule.

Topical broad-spectrum antiviral therapeutic for orofecal and sexually transmitted diseases.

UCLA researchers have discovered a compound for broad antiviral therapy. The compound modifies cellular membranes and disrupts virus-host integration, an essential step for viral entry. This mode of action is different from both commercially available antivirals and drugs in pharmaceutical pipelines, offering a plausible alternative development strategy. UCLA researchers have demonstrated the compound to be effective against eight viral types. Further, inhibitory effect was successfully demonstrated in vivo against HIV. Importantly, this molecule is an endogenously-produced antiviral factor. It is thus likely to be well-tolerated in the body.

Inventor: CHENG, Genhong | LIU, Su-Yang
Priority Number: WO2013166503A1
IPC Current: A61K003156 | A61P003100 | A61P003112
Assignee Applicant: The Regents of the University of California
Title: BROAD ANTIVIRAL THERAPY WITH MEMBRANE MODIFYING OXYSTEROLS | THÉRAPIE ANTIVIRALE LARGE PAR DES OXYSTÉROLS DE MODIFICATION DE MEMBRANE
Usefulness: BROAD ANTIVIRAL THERAPY WITH MEMBRANE MODIFYING OXYSTEROLS | THÉRAPIE ANTIVIRALE LARGE PAR DES OXYSTÉROLS DE MODIFICATION DE MEMBRANE
Summary: The method is useful for in vitro inhibition or prevention of a viral infection of a mammalian cell, or inhibiting the growth and/or proliferation and/or the entry of the virus such as VSV, HSV, MHV68, HCV, HIV, EBOV, or Nipah virus into a cell, preferably a human or nonhuman mammalian cell (all claimed). Tests details are described but no results given.

診斷/治療

人類免疫缺陷病毒

State Of Development

• The antiviral effect has been demonstrated against eight viruses, namely, Ebola virus, HIV, hepatitis C virus, vesicular stomatitis virus, herpes simplex virus, murine gammaherpesvirus, Rift Valley fever virus, and Russian spring-summer encephalitis virus.
• The compound has been shown to reduce HIV replication in humanized mouse models.
• Derivative compounds with greater and more specific action are under development.  

Background

Virus-borne diseases represent a significant proportion of infectious diseases worldwide. These diseases, including Hepatitis C and AIDS, affect millions of people, are often life-threatening, and have enormous economic impacts; the global market for Hepatitis C is estimated at ~$4.5 billion and ~$11 billion for HIV. Thus, drugs targeting a broad spectrum of viral types would have enormous market potential. However, almost all of the commercially available therapies are specific for particular viruses. The few "broad-spectrum" drugs, such as ribavirin, are effective only against a limited number of viral types. They also cause debilitating side effects, limiting the dosages to suboptimal levels. A "penicillin-like" antiviral therapy is essentially absent in the current marketplace, and few broad-spectrum antivirals are past the preclinical stage. Therapeutic approaches to treat a wide range of pathogenic viruses are therefore highly desirable

Related Materials

Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol.

Additional Technologies by these Inventors

• Receptor Interacting Protein 2 (rip2) in Development of Immune Response
• Generation Of A Live Attenuated Influenza Vaccine That Elicits Broad Protection

Tech ID/UC Case

23219/2012-742-0

Related Cases

2012-742-0

美國

桌面版